Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL -November 02, 2023 at 10:38 am EDT

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 --...

Related Keywords

Spain ,San Diego ,California ,United States ,San Diego Convention Center ,Barcelona ,Comunidad Autonoma De Cataluna ,American ,Bruce Mackle ,Mark Guerin ,Nuria Profitos Peleja ,Steven Fruchtman ,Company Contact ,American Society For Hematology Annual Meeting Exposition ,Josep Carreras Leukaemia Research Institute ,Globenewswire Inc ,Onconova Therapeutics Inc ,Nasdaq ,Securities Exchange ,Lymphoma Translational Group ,Lifesci Advisors ,Hematology Annual Meeting ,Carreras Leukaemia Research Institute ,Presentation Information ,Prolongs Cell Cycle Arrest ,Metabolomic Reprogramming ,Enabling Restoration ,Ibrutinib Sensitivity ,Btki Resistant Mantle Cell ,Drug Resistance ,Lymphoid Neoplasms ,Diego Convention Center ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Annual Report ,Sci Advisors ,Markets ,